Fidelity MSCI Health Care Index ETF FHLC
90.29 USD +0.09 (+0.10%)
At closeNov 11, 2026, 4:00 PM EST
90.25 -0.04 -0.04%
After hours · Nov 11, 4:00 PM ET
89.37 Day range 90.44
68.53 52-week range 90.77
- YTD
- +21.55%
- 1 year
- +24.68%
News
247wallst.com Fidelity's Health Care ETF Holds the Biotechs XLV Skips. Retirees Should Know the Difference Two health care ETFs track the same sector but own very different slices of it, and for retirees building a portfolio, that gap in biotech exposure and concentration could matter more than the nearly…
fool.com Which Healthcare ETF Is the Better Buy: Fidelity's FHLC or State Street's XLV? State Street Health Care Select Sector SPDR ETF focuses exclusively on S&P 500 healthcare components, leading to a highly concentrated portfolio. Fidelity MSCI Health Care Index ETF provides broader…
defenseworld.net 7,458 Shares in Fidelity MSCI Health Care Index ETF $FHLC Purchased by LexAurum Advisors LLC LexAurum Advisors LLC bought a new stake in Fidelity MSCI Health Care Index ETF (NYSEARCA:FHLC) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange…
fool.com Better Buy: Fidelity Health Care ETF (FHLC) or iShares Biotechnology ETF (IBB)? Fidelity MSCI Health Care Index ETF offers a significantly lower expense ratio of 0.08% compared to 0.44% for the iShares Biotechnology ETF. iShares Biotechnology ETF is more concentrated, with 87%…
fool.com Which Healthcare ETF Is the Better Buy: Fidelity’s Broad FHLC or Invesco’s Biotech-Focused PBE? One offers broad diversification at 0.08% cost, while the other targets concentrated biotech growth with higher volatility.
defenseworld.net Rockland Trust Co. Buys 28,319 Shares of Fidelity MSCI Health Care Index ETF $FHLC Rockland Trust Co. bought a new position in shares of Fidelity MSCI Health Care Index ETF (NYSEARCA:FHLC) in the third quarter, according to its most recent Form 13F filing with the Securities and…
fool.com Better Healthcare ETF: Fidelity's Broad, Low-Cost FHLC vs. State Street's XBI Targeting Biotech The Fidelity MSCI Health Care Index ETF offers a significantly lower expense ratio and a more diversified portfolio than the State Street SPDR S&P Biotech ETF. The State Street SPDR S&P Biotech ETF…
fool.com Fidelity Healthcare ETF (FHLC) vs. VanEck Biotech ETF (BBH): Which Fund Is the Better Buy? FHLC features a much lower expense ratio of 0.08% compared to 0.35% for BBH. BBH is a concentrated portfolio of just 26 stocks, while FHLC holds around 350 companies.
fool.com Does Fidelity or iShares Have the Better Healthcare ETF For Investors Seeking Broad Exposure? Fidelity MSCI Health Care Index ETF has a significantly lower expense ratio than iShares Global Healthcare ETF. iShares Global Healthcare ETF provides exposure to international healthcare markets,…
zacks.com Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)? Designed to provide broad exposure to the Healthcare - Broad segment of the equity market, the Fidelity MSCI Health Care Index ETF (FHLC) is a passively managed exchange traded fund launched on…
etftrends.com Tackle Market Uncertainty With Strategic Healthcare Exposure With much of the attention in the capital markets directed towards the technology sector, it's easy to forget other sectors like healthcare. However, it's key to consider other sectors within your…
fool.com Which Is the Better Healthcare ETF: Fidelity's Low-Cost FHLC or First Trust's High-Conviction FBT? One fund offers broad sector exposure at 0.08% cost; the other concentrates on 30 biotech stocks with higher volatility but stronger recent returns.
fool.com Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH? FHLC captures the whole healthcare opportunity at rock-bottom cost. XPH narrows the bet to pharmaceuticals and charges significantly more for it.
fool.com Healthcare ETF Comparison: Fidelity's FHLC vs. Invesco's Biotech-Focused IBBQ The Fidelity MSCI Health Care Index ETF features a lower expense ratio of 0.08% and a higher dividend yield of 1.2%. The Invesco Nasdaq Biotechnology ETF has delivered a higher 1-year total return of…
fool.com Fidelity vs VanEck Healthcare ETFs: Broad Exposure or Pharma Focus VanEck's concentrated 26-stock portfolio has outpaced Fidelity's broader 334-holding fund over five years, but at a steeper cost and higher volatility.
fool.com FHLC vs. PJP: Which Healthcare ETF Is the Better Buy for Investors? Fidelity MSCI Health Care Index ETF (FHLC) offers a significantly lower expense ratio and a higher dividend yield than the Invesco Pharmaceuticals ETF (PJP). PJP provides a concentrated portfolio of…
fool.com Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins? Fidelity's lower 0.08% fee and broader 338-stock portfolio contrast sharply with iShares' concentrated pharma play, which delivered 60% returns in one year.
fool.com Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or Simplify's Actively Managed PINK? Fidelity MSCI Health Care Index ETF provides low-cost, broad-market exposure with an expense ratio of 0.08%. Simplify Health Care ETF uses active management and a philanthropic model to target…
fool.com Healthcare Stocks Are Having a Good Year. Should You Buy a Fidelity or iShares ETF to Profit? Fidelity MSCI Health Care Index ETF carries a significantly lower expense ratio of 0.08% compared to 0.38% for iShares U.S. Healthcare ETF Fidelity MSCI Health Care Index ETF provides broader…
fool.com Which Healthcare ETF Is the Better Buy: Fidelity's FHLC or Invesco's Equal-Weight RSPH? FHLC's 0.08% expense ratio and market-cap approach delivered stronger returns, while RSPH's equal-weight strategy offers lower volatility and broader diversification across 60 holdings.
benzinga.com UnitedHealth Rally Sparks Bullish Case for Healthcare ETFs Despite Medicare Advantage Losses UnitedHealth's (UNH) strong earnings and raised outlook lifted healthcare ETFs despite a sharp decline in Medicare Advantage membership.
benzinga.com White House Reportedly Preparing To Oust FDA Commissioner Marty Makary Trump considers Kyle Diamantas for acting FDA chief as Marty Makary faces potential removal. Stay updated on the leadership transition.
benzinga.com Federal Judge Halts National Institutes of Health's Grant Policy Overhaul Citing Legal Violations A federal court blocked NIH's policy capping indirect cost rates on research grants, ruling it unlawful. The decision safeguards billions in funding and ongoing clinical trials.
benzinga.com NIH Funding Cuts To Spook Healthcare Stocks? RFK Jr's Confirmation At HHS Sparks Concerns Over Research Dollars, 'Causing Uncertainty,' Says Analyst Robert F. Kennedy Jr.'s appointment as Secretary of Health and Human Services has sparked concerns over funding for the NIH.
benzinga.com Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024 According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.
benzinga.com Lab-Developed Tests Under FDA Scrutiny: What It Means For Startups A proposed regulatory shift has injected uncertainty into the laboratory-testing market just as startups advance various tests to detect diseases sooner and personalize treatments.
benzinga.com From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&A and investments. This significant financial reserve will be crucial as…- benzinga.com Fidelity Trims Fees on 3 Bond ETFs
benzinga.com Heaps Of Healthy Health Care ETFs - benzinga.com Previewing Fidelity's Upcoming Low Volatility ETF
benzinga.com Fidelity Fires Back At Vanguard With Sector ETF Fee Cuts - benzinga.com The Other Sector ETF Player
- benzinga.com Brokerage Giants Expand In ETF Space
benzinga.com Healthcare ETFs Unmoved By Possible Humana Inc. Merger